-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 25th, Lilly Pharmaceuticals developed the classic anti-tumor chemotherapy drug Libita (injection of permeitus dsodium) in the Alliance region drug centralized procurement bid. The winning bid price for this injection is 100mg-809 yuan/box, 500mg-2773.64 yuan/box, a decrease of more than 60%.
July this year, in response to the implementation of the country's first wave of "4 plus 7" urban collection of drugs related policies, Lilly took the initiative to reduce the price of injection of permeitus diazeth, when the price reduction of about 30%. The winning bid for the "4 plus 7" band purchase expansion further reduced the price of sodium dissemia for injection with peme queces. The reduction in the price of the drug has helped to reduce the financial burden on the families and society of the related diseases.
"We are very pleased to participate in the centralized procurement of drugs in the alliance region and ultimately win the bid," said Mr. Qian Jiang, Vice President of Lilly's China Anti-Oncology Division. "After the first tender last year, the company and its headquarters have always maintained active communication, first by actively reducing the price of injectable peme querceonse, and this time by a further 60% reduction to ensure the winning bid." Lilly prioritizes patient benefits and hopes this will help more cancer patients gain access to high-quality primary drugs. "
injection of permeycean diazepine as one of the classic anti-tumor drugs of Lilly's anti-tumor division, was approved by the State Food and Drug Administration in 2005 for the treatment of malignant pleural mesothelioma. In June 2011, it was approved for "secondary and maintenance therapy for advanced or metastatic non-small cell lung cancer." In June 2014, it was approved for use in localized advanced or metastatic non-small cell lung cancer and continued to maintain the treatment of new indications. To date, more than 60,000 patients have been assisted.
.
